title: Retinoid Chemoprevention: Who Can Benefit?
abstract: Acute promyelocytic leukemia (APL) is a treatment success story. From a highly deadly disease it was turned into a highly curable disease by the introduction of differentiation-induction therapy with all-trans retinoic acid (ATRA) in the 1990's. During the last quarter of century, ATRA and other retinoids were used for the treatment and prevention of other cancers and even other diseases. The results were less spectacular, but nevertheless important. Progress has been made toward understanding the mechanism of action of retinoids in different physiological and pathological contexts. For some diseases, specific genetic backgrounds were found to confer responsiveness to retinoid therapy. Therapies that include retinoids and other modalities are very diverse and used both for combined targeting of multiple pathways and for diminishing toxicity.
authors.affiliation: Department of Biomedical Sciences, Cornell University, Ithaca, NY, 14853, USA.
authors.forename: Rodica P
authors.initials: RP
authors.lastname: Bunaciu
authors.affiliation: Department of Biomedical Sciences, Cornell University, Ithaca, NY, 14853, USA.
authors.forename: Andrew
authors.initials: A
authors.lastname: Yen
keywords: chemoprevention; retinoic acid signaling; retinoid